A genotyping method for VKORC1 1173C>T by Pyrosequencing® technology

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 5, 2008, Pages 427-430

  Enström, Camilla ^a   Osman, Abdimajid ^a   Lindahl, Tomas L ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulation; Pharmacogenetics; Polymorphism; Vitamin K epoxide reductase; Warfarin

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 50449088681     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701810621     Document Type: Article

References (14)

1. Stenflo J, Fernlund P, Egan W, Roepstrff.. Vitamin K dependent modification of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA 1974;71:2730-3.
2. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978;17:1371-7.
3. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
4. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004;427:541-4.
5. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
6. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005;94:773-9.
7. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
8. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70.
9. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum Mol Genet 2005;14:1745-51.
10. Osman A, Enstrom C, Arbring K, Soderkvist P, Lindahl TL. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. J Thromb Haemost 2006;4:1723-9.
11. Hatch E, Sconce EA, Daly AK, Kamali F. A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. J Thromb Haemost 2006;4:1158-9.
12. Jannetto PJ, Laleli-Sahin E, Wong SH. Pharmacogenomic genotyping methodologies. Clin Chem Lab Med 2004;42:1256-64.
13. Alderborn A, Kristofferson A, Hammerling U. Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. Genome Res 2000;10:1249-58.
14. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998;281:363-5.